Summary:
There has been a new innovation developed by the team of researchers at the medical university in Martin region in Slovakia. Compared to existing solutions simplier triFFY (trisomic fetal fraction) method for fetal fraction determination in Non-invasive Prenatal Screening (NIP) is now available for commercial purposes. The institution is looking for a partner to license the technology.
Description:
In the read-counting approach to Non-invasive Prenatal Screening (NIPS) the aneuploidy status of a fetus/placenta is determined using the read representation of a chromosome and fetal fraction. Several in silico methods for fetal fraction determination are available and they estimate fetal fraction with different degree of precision and have different limitations. One of the most precise among them is the ffY method, which works for pregnancies with male placenta/fetus, only. The method requires sequencing a set of adult males.
A team of researchers at the Slovak university in Martin has developed a method – triFFY (trisomic fetal fraction) - for fetal fraction determination in pregnancies with male fetus which utilizes information from a small set of pregnancies with trisomic male placenta/fetus and the read representation of chromosome Y to predict fetal fraction for a sample from pregnancy with male placenta/fetus.
The institution is looking for an industrial partner for licensing, further development and commercionalization of the mentioned method.
Type (e.g. company, R&D institution…), field of industry and Role of Partner Sought:
The R&D institution is seeking an industrial partner for licensing the technology. Field of activity: the new technology is applicable in the medical field. Role of partner: - license agreement - the licensing for the further development and commercionalization of this technology is sought.
Stage of Development:
Available for demonstration
IPR Status:
Patent(s) applied for but not yet granted
External code:
TOSK20211025003
